{"product_id":"reparixin-cxcr1-2-allosteric-antagonist-tbi2527","title":"Reparixin, CXCR1\/2 allosteric antagonist","description":"\u003cp\u003e\u003cspan style=\"font-size: 18px\"\u003e\u003cstrong\u003e\u003cu\u003eProduct Details\u003c\/u\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFormal Name: \u003c\/strong\u003eαR-Methyl-4-(2-methylpropyl)-N-(methylsulfonyl)-benzeneacetamide\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAlternate Names: \u003c\/strong\u003eDF 1681Y; Repertaxin\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e14\u003c\/sub\u003eH\u003csub\u003e21\u003c\/sub\u003eNO\u003csub\u003e3\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFormula Weight:\u003c\/strong\u003e 283.39\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCAS Number:\u003c\/strong\u003e 266359-83-5\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePurity:\u003c\/strong\u003e \u0026gt;98%\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFormulation:\u003c\/strong\u003e powder\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSolubility:\u003c\/strong\u003e Soluble in DMSO (up to 100 mg\/ml) or in Ethanol up to 25 mg\/ml)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e -20°C\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eStability:\u003c\/strong\u003e ≥ 1 year.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 18px\"\u003e\u003cstrong\u003e\u003cu\u003eApplications\u003c\/u\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eCXCR1\/2 allosteric antagonist\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 18px\"\u003e\u003cstrong\u003e\u003cu\u003eFunctions\u003c\/u\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eReparixin is a noncompetitive allosteric inhibitor of IL-8 (CXCL8) activation of CXCR1 and CXCR2 chemokine receptors (IC50 = 1 and 100 nM, respectively). It blocks a number of activities related to IL-8 signaling, including leukocyte recruitment (IC50 = 1 nM) without affecting receptor activation induced by other CXCR1 and CXCR2 agonists. In spontaneously hypertensive rats, 5 mg\/kg reparixin administered daily for three weeks was shown to reduce blood pressure by inhibiting hypertension-related mediators. It attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. Reparixin blockade (100 nM) of CXCR1 has also been used to deplete a cancer stem cell population in human breast cancer cell lines in vitro.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 18px\"\u003e\u003cstrong\u003e\u003cu\u003eApplication Procedures\u003c\/u\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003eFirst dissolved in DMSO (up to 100 mg\/ml) or in Ethanol up to 25 mg\/ml), then diluted to aqueous buffer. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.\u003c\/p\u003e\n\u003cp\u003e\u003c!--TBI2527-5MG TBI2527-25MG--\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"font-size: 13px; font-weight: 700; text-transform: uppercase;\"\u003e\u003cstrong\u003eResearch use only.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch2\u003eDocuments\u003c\/h2\u003e\n\u003cul\u003e\u003cli\u003e\u003ca href=\"https:\/\/tribioscience.com\/wp-content\/uploads\/2023\/08\/TBI2527_Data_Sheet-1.pdf\"\u003eDatasheet (PDF)\u003c\/a\u003e\u003c\/li\u003e\u003c\/ul\u003e","brand":"TriBioScience","offers":[{"title":"5 mg","offer_id":45986661367887,"sku":"TBI2527-5MG","price":429.0,"currency_code":"ILS","in_stock":true},{"title":"25 mg","offer_id":45986661400655,"sku":"TBI2527-25MG","price":1705.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/TBI2527.png?v=1782816222","url":"https:\/\/www.danyel.co.il\/products\/reparixin-cxcr1-2-allosteric-antagonist-tbi2527","provider":"danyel biotech","version":"1.0","type":"link"}